Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522196 · ClinicalTrials.gov registry record · Phase 2
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01522196 is a Phase 2 study that was terminated before completion, run by Anthera Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT01522196, a Phase 2 study, was terminated before completion, sponsored by Anthera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
Interventions
- OTHER Placebo (Normal Saline)
- DRUG Varespladib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522196
The ClinicalTrials.gov registry entry for NCT01522196 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (Normal Saline) is the first listed.
NCT01522196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522196 about?
NCT01522196 is a clinical study titled "A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.". The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
What is the current status of trial NCT01522196?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01522196?
The interventions under investigation include: Placebo (Normal Saline) (OTHER), Varespladib (DRUG).
Who is sponsoring clinical trial NCT01522196?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.